Indinavir: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 13: | Line 13: | ||
{| class="wikitable" border="1" width="52%" style="text-align:center" | {| class="wikitable" border="1" width="52%" style="text-align:center" | ||
|- | |- | ||
! colspan="12" align="center"| HIV Protease Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>PMID:20400409</ref><ref>Ferry et al, United States Patent US6147095, Pharmacia & Upjohn Company.</ref> | ! colspan="12" align="center"| HIV Protease Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>PMID:20400409</ref><ref>Ferry et al, United States Patent US6147095, Pharmacia & Upjohn Company.</ref><ref>L. Veronese et al. Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function. Antimicrob Agents Chemother. 2000 April; 44(4): 821–826.</ref><ref>doi: 10.1128/AAC.48.7.2388-2393.2004.</ref> | ||
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 45: | Line 45: | ||
! 14600 | ! 14600 | ||
! Indinavir | ! Indinavir | ||
! | ! 1540 | ||
! 4901 | ! 4901 | ||
! Fosamprenavir | ! Fosamprenavir | ||
| Line 84: | Line 84: | ||
! 4.2 | ! 4.2 | ||
! 1.8 | ! 1.8 | ||
! | ! 4.5 | ||
! 5.56 | ! 5.56 | ||
! Fosamprenavir | ! Fosamprenavir | ||
| Line 97: | Line 97: | ||
! 46500 | ! 46500 | ||
! Indinavir | ! Indinavir | ||
! | ! 16200 | ||
! 11999 | ! 11999 | ||
! Fosamprenavir | ! Fosamprenavir | ||
